Citation
Braun, Julian, et al. "SARS-CoV-2-reactive T Cells in Healthy Donors and Patients With COVID-19." Nature, vol. 587, no. 7833, 2020, pp. 270-274.
Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587(7833):270-274.
Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K., Röhmel, J., Voigt, S., Schmitz, J., ... Thiel, A. (2020). SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature, 587(7833), 270-274. https://doi.org/10.1038/s41586-020-2598-9
Braun J, et al. SARS-CoV-2-reactive T Cells in Healthy Donors and Patients With COVID-19. Nature. 2020;587(7833):270-274. PubMed PMID: 32726801.
TY - JOUR
T1 - SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
AU - Braun,Julian,
AU - Loyal,Lucie,
AU - Frentsch,Marco,
AU - Wendisch,Daniel,
AU - Georg,Philipp,
AU - Kurth,Florian,
AU - Hippenstiel,Stefan,
AU - Dingeldey,Manuela,
AU - Kruse,Beate,
AU - Fauchere,Florent,
AU - Baysal,Emre,
AU - Mangold,Maike,
AU - Henze,Larissa,
AU - Lauster,Roland,
AU - Mall,Marcus A,
AU - Beyer,Kirsten,
AU - Röhmel,Jobst,
AU - Voigt,Sebastian,
AU - Schmitz,Jürgen,
AU - Miltenyi,Stefan,
AU - Demuth,Ilja,
AU - Müller,Marcel A,
AU - Hocke,Andreas,
AU - Witzenrath,Martin,
AU - Suttorp,Norbert,
AU - Kern,Florian,
AU - Reimer,Ulf,
AU - Wenschuh,Holger,
AU - Drosten,Christian,
AU - Corman,Victor M,
AU - Giesecke-Thiel,Claudia,
AU - Sander,Leif Erik,
AU - Thiel,Andreas,
Y1 - 2020/07/29/
PY - 2020/04/09/received
PY - 2020/07/22/accepted
PY - 2020/7/30/pubmed
PY - 2020/11/20/medline
PY - 2020/7/30/entrez
SP - 270
EP - 274
JF - Nature
JO - Nature
VL - 587
IS - 7833
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic1,2. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4+ T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4+ T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4+ T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.
SN - 1476-4687
UR - https://www.unboundmedicine.com/medline/citation/32726801/SARS_CoV_2_reactive_T_cells_in_healthy_donors_and_patients_with_COVID_19_
L2 - https://doi.org/10.1038/s41586-020-2598-9
DB - PRIME
DP - Unbound Medicine
ER -
